Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SK Bioscience Readies $1.3bn IPO Amid Rosy Vaccine Outlook

Expects Continued Rise In COVID-19 Vaccine Demand

Executive Summary

Vaccine specialist SK Bioscience is set to launch potentially South Korea’s biggest biopharma IPO next month on the back of a growing premium vaccine business, new opportunities in COVID-19 vaccines and its contract manufacturing operations.

You may also be interested in...



Korean Bio/Healthcare Sector Sees Ample Fund Inflows In 2021

Financing for Korean bioventures and pharma firms remained strong this year amid ample liquidity and strong investor sentiment in the sector. SK Bioscience's IPO was the top fundraiser in 2021, followed by HK inno.N’s offering, while GI Innovation raised the most money from venture capital sources.

Large-Scale Funding Rises In Korea Amid Biotech Investment Boom

After record venture capital activity around South Korean biotechs last year, the strong investment interest has persisted so far this year, with an increased number of companies receiving large-scale funding as the promising sector emerges amid the pandemic.

Korean Biopharma IPOs Start Strong With Prestige

Following a successful offering by Prestige BioPharma in January, investors will keep their focus on another upcoming major listing by the SK Group's specialist vaccines arm SK Bioscience, which is likely to set the tone for the South Korean biopharma IPO market this year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143875

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel